Test performance characteristics of anti-HEV IgG assays strongly influence hepatitis e seroprevalence estimates

164Citations
Citations of this article
89Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Hepatitis E virus (HEV) seroprevalences of 0.3%-53% were reported from industrialized countries. Because these estimates may be influenced by detection assays, this study compares 3 frequently used tests for HEV detection: the MP Diagnostics HEV immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA), the Axiom Diagnostics HEV IgG enzyme immunoassay (EIA), and the Mikrogen recomLine HEV IgG assay. Sera from 200 healthy healthcare workers and 30 individuals with acute HEV infection were analyzed. Among the healthy individuals, HEV IgG was found in 4.5% by the MP Diagnostics assay, in 29.5% by the Axiom Diagnostics assay, and in 18% by the Mikrogen assay. Among individuals with acute HEV infection, positive results were obtained for 83.3%, 100%, and 96.7%, respectively. Thus, the 3 assays show clear differences in diagnostic sensitivity. © 2012 The Author.

Cite

CITATION STYLE

APA

Wenzel, J. J., Preiss, J., Schemmerer, M., Huber, B., & Jilg, W. (2013). Test performance characteristics of anti-HEV IgG assays strongly influence hepatitis e seroprevalence estimates. Journal of Infectious Diseases, 207(3), 497–500. https://doi.org/10.1093/infdis/jis688

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free